Gary H Lyman Selected Research

Drug Therapy (Chemotherapy)

05/2008	Development and validation of a predictive model for chemotherapy-associated thrombosis.
03/2008	Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.
02/2008	Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.
10/2007	Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
07/2007	Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
02/2007	Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
12/2006	Chemotherapy dose intensity and quality cancer care.
07/2006	Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.
01/2006	Risks and consequences of chemotherapy-induced neutropenia.
01/2006	Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review.
12/2005	Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.
11/2005	Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry.
07/2005	Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
06/2005	Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
06/2005	Undertreatment of obese women receiving breast cancer chemotherapy.
06/2005	Risk models for predicting chemotherapy-induced neutropenia.
05/2005	Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
03/2005	The economic burden of anemia in cancer patients receiving chemotherapy.
01/2005	Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
11/2004	Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
08/2004	Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches.
07/2004	Prophylactic pegfilgrastim significantly reduces febrile neutropenia during moderately myelosuppressive chemotherapy.
05/2004	A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer.
04/2004	Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.
01/2004	Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
12/2003	Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
12/2003	Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.
12/2003	Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
11/2003	Cost effectiveness of myeloid growth factors in cancer chemotherapy.
04/2002	Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.

Articles by Research Topic

Disease

18	Neoplasms (Cancer) 03/2008 - 04/2002
17	Neutropenia 07/2007 - 01/2002
7	Breast Neoplasms (Breast Cancer) 06/2007 - 12/2003
3	Anemia 07/2006 - 03/2005
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2004 - 12/2003
1	Thrombosis (Thrombus) 05/2008
1	Hemorrhage 09/2007
1	Venous Thromboembolism 12/2005
1	Alopecia (Baldness) 08/2004

Drug/Important Bio-Agent (IBA)

5	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 01/2007 - 11/2003
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2007 - 04/2002
2	pegfilgrastim (Neulasta)FDA Link 03/2008 - 07/2004
2	Anti-Bacterial Agents (Antibiotics)IBA 03/2006 - 06/2004
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2005 - 11/2003
1	AnticoagulantsIBA 09/2007
1	Proteins (Proteins, Gene)IBA 07/2006
1	Estrogens (Estrogen)FDA Link 05/2005
1	Paclitaxel (Taxol)FDA LinkGeneric 05/2004
1	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2004
1	ErythropoietinIBA 01/2004
1	Filgrastim (Neupogen)FDA Link 01/2002

Therapy/Procedure

30	Drug Therapy (Chemotherapy) 05/2008 - 04/2002
3	Adjuvant Chemotherapy 06/2007 - 12/2006
1	Length of Stay 11/2005